ArticleAlzheimer's research & therapy2026
p75 neurotrophin receptor shapes the dynamics of adult hippocampal neurogenesis in Alzheimer's disease.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAlzheimer’s Disease (AD) is a neurodegenerative disorder primarily characterized by memory loss and cognitive decline. The AD-driven impairment of adult hippocampal neurogenesis - the process of generating new neurons in the dentate gyrus - is strongly implicated in this cognitive failure. Adult Neurogenesis is dependent on neurotrophin signaling, with the p75 pan-neurotrophin receptor (p75NTR) specific role to remain unclear under both physiological or pathological conditions. In the present study, we explore how p75NTR influences adult neurogenesis under both physiological and neurodegenerative conditions, focusing on AD.
methodsWe used the amyloidogenic 5xFAD mouse model of AD, as well as p75NTR full and conditional knockout mice. Moreover, we have generated a 5xFAD/p75NTR knockout model to directly examine the connective role of p75NTR in adult neurogenesis and AD. We have tempo-spatially evaluated the impact of p75NTR, by performing 5-bromo-2′-deoxyuridine injections to detect neural stem cell proliferation and immunohistochemistry analysis for key neurogenic markers. Additionally, transcriptomic profiling identified p75NTR-dependent gene networks. To extend findings to humans and provide translational relevance, we investigated p75NTR effects in human induced Pluripotent Stem Cells-derived Neural Stem Cells (iPSCs-derived NSCs), depicting receptor’s signaling in the presence of toxic Amyloid-β.
resultsDeletion of p75NTR in mice led to reduced NSC proliferation, altered differentiation, and decreased survival of neurons in the dentate gyrus, while our results from conditional knockout lines suggest that p75NTR regulates these processes through mechanisms extending beyond NSCs. Under AD and specifically in 5xFAD mice, neurogenesis was transiently increased at early stages but subsequently declined. This compensatory response was absent in 5xFAD/p75NTR knock out mutants, which exhibited exacerbated deficits, indicating a p75NTR-dependent disease modification. Transcriptomic analyses revealed gene networks consistent with changes in proliferation, differentiation, and survival. Finally, in human iPSCs-derived NSCs, p75NTR expression was confirmed, and receptor inhibition significantly reduced amyloid-β–induced toxicity, pointing to conserved functions across species.
conclusionsTogether, these findings support a significant role for p75NTR in regulating hippocampal neurogenesis under both physiological and AD-related conditions. By linking p75NTR function to both rodent and human neural stem cell responses, this study highlights that p75NTR is not only critical for maintaining neurogenesis but also represents a candidate target for future therapeutic exploration in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.